Use of chemical disinfectants might increase the risk of chronic obstructive pulmonary disease (COPD) in nurses, a study suggests. The study, “Association of Occupational Exposure to Disinfectants With Incidence of Chronic Obstructive Pulmonary Disease Among US Female Nurses,” was published in the journal JAMA Network…
In recognition of Rare Disease Day Feb. 29, Bionews Services launched a social media campaign last month asking patients to describe what makes them rare. Running Feb. 7–29, the #WhatMakesMeRare campaign was aimed at uplifting people with rare diseases by encouraging them to share their stories and perspectives. The…
You literally can’t miss it in the news these days — millions (if not billions) of people all over the world are talking about the increasing spread of “the new (novel) Coronavirus.” According to the Center for Disease Control (CDC), the earliest cases of COVID-19 began in the city of…
Signant Health and Propeller Health are connecting their systems to help improve asthma and chronic obstructive pulmonary disease (COPD) patients’ adherence to inhaled medication and symptom control. Signant said it will connect its TrialMax electronic clinical outcome assessment (eCOA) platform to Propeller’s digital health platform for…
Verona Pharma announced positive top-line results on the use of nebulized ensifentrine as an add-on to tiotropium (Spiriva Respimat) in people with moderate-to-severe chronic obstructive pulmonary disease (COPD). The results come from a Phase 2b clinical trial (NCT03937479), which showed that ensifentrine — when…
New York cardiopulmonary physical therapist Noah Greenspan has launched the Pulmonary Wellness Foundation (PWF), a nonprofit group that provides free online information on a range of prevalent, rare and ultra-rare pulmonary diseases for those who can’t afford to pay for it. PWF specifically targets patients with pulmonary fibrosis,…
A new double-combination therapy that promotes lung expansion and airway clearance has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of people with lung diseases including chronic obstructive pulmonary disease (COPD) and asthma. The therapy was developed by the Monaghan Medical Corporation and combines two…
Cancer therapies blocking specific protein receptors called ErbB reduced inflammation in animal models of inflammatory diseases — including those affecting the lung — by destroying neutrophils, a type of immune cell, a preclinical study found. According to the researchers, these findings suggest that treatments blocking the activity…
A newly developed assisted breathing device, based on the principles of older mechanical respirators but with more convenience and power, may soon be available for people with lung diseases who have trouble breathing. The Right Air vest is a small, powerful device to assist breathing that can be used…
AstraZeneca’s triple-combination therapy for people with chronic obstructive pulmonary disease (COPD) has been approved in China as a maintenance treatment. The therapy comprises three compounds: the corticosteroid budesonide, and two long-acting bronchodilators — glycopyrronium, a muscarinic antagonist, and formoterol fumarate, a β2-agonist. This combo…
Get regular updates to your inbox.